Immunologic abnormalities in chronic fatigue syndrome

N. G. Klimas, F. R. Salvato, R. Morgan, M. A. Fletcher

Research output: Contribution to journalArticle

374 Citations (Scopus)

Abstract

The chronic fatigue syndrome (CFS), formerly known as chronic Epstein-Barr virus syndrome, is a clinical state of some complexity and uncertain etiology. In order to characterize in a comprehensive manner the status of laboratory markers associated with cellular immune function in patients with this syndrome, 30 patients with clinically defined CFS were studied. All of the subjects were found to have multiple abnormalities in these markers. The most consistent immunological abnormality detected among these patients, when compared with normal controls, was low natural killer (NK) cell cytotoxicity. The number of NK cells, as defined by reactivity with monoclonal antibody NKH.1 (CD56), was elevated, but the killing of K562 tumor cells per CD56 cell was significantly diminished. Lymphoproliferative responses after stimulation with phytohemagglutinin and pokeweed mitogen were decreased in most patients when compared with those in normal controls, as was the production of gamma interferon following mitogen stimulation. Lymphocyte phenotypic marker analysis of peripheral blood lymphocytes showed that there were significant differences between patients with CFS and controls. There was an increase in the percentage of suppressor-cytotoxic T lymphocytes, CD8, and a proportionally larger increase in the number of CD8 cells expressing the class II activation marker. Most patients had an elevated number of CD2 cells which expressed the activation marker CDw26. The numbers of CD4 cells and the helper subset of CD4+ CD29+ cells in patients with CFS were not different from those in controls. There was, however, a significant decrease in the suppressor inducer subset of CD4+ CD45RA+ cells. The numbers of B cells, CD20 and CD21, were elevated, as were the numbers of a subset of B cells which coexpressed CD20 and CD5. The pattern of immune marker abnormalities observed was compatible with a chronic viral reactivation syndrome.

Original languageEnglish
Pages (from-to)1403-1410
Number of pages8
JournalJournal of Clinical Microbiology
Volume28
Issue number6
StatePublished - Jun 18 1990
Externally publishedYes

Fingerprint

Chronic Fatigue Syndrome
Cell Count
Natural Killer Cells
Biomarkers
Lymphocytes
Multiple Abnormalities
B-Lymphocyte Subsets
Pokeweed Mitogens
K562 Cells
Cytotoxic T-Lymphocytes
Phytohemagglutinins
Helper-Inducer T-Lymphocytes
Human Herpesvirus 4
Mitogens
Interferon-gamma
B-Lymphocytes
Monoclonal Antibodies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Klimas, N. G., Salvato, F. R., Morgan, R., & Fletcher, M. A. (1990). Immunologic abnormalities in chronic fatigue syndrome. Journal of Clinical Microbiology, 28(6), 1403-1410.

Immunologic abnormalities in chronic fatigue syndrome. / Klimas, N. G.; Salvato, F. R.; Morgan, R.; Fletcher, M. A.

In: Journal of Clinical Microbiology, Vol. 28, No. 6, 18.06.1990, p. 1403-1410.

Research output: Contribution to journalArticle

Klimas, NG, Salvato, FR, Morgan, R & Fletcher, MA 1990, 'Immunologic abnormalities in chronic fatigue syndrome', Journal of Clinical Microbiology, vol. 28, no. 6, pp. 1403-1410.
Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. Journal of Clinical Microbiology. 1990 Jun 18;28(6):1403-1410.
Klimas, N. G. ; Salvato, F. R. ; Morgan, R. ; Fletcher, M. A. / Immunologic abnormalities in chronic fatigue syndrome. In: Journal of Clinical Microbiology. 1990 ; Vol. 28, No. 6. pp. 1403-1410.
@article{2176dd730aec4a3d9575b9bef52ed668,
title = "Immunologic abnormalities in chronic fatigue syndrome",
abstract = "The chronic fatigue syndrome (CFS), formerly known as chronic Epstein-Barr virus syndrome, is a clinical state of some complexity and uncertain etiology. In order to characterize in a comprehensive manner the status of laboratory markers associated with cellular immune function in patients with this syndrome, 30 patients with clinically defined CFS were studied. All of the subjects were found to have multiple abnormalities in these markers. The most consistent immunological abnormality detected among these patients, when compared with normal controls, was low natural killer (NK) cell cytotoxicity. The number of NK cells, as defined by reactivity with monoclonal antibody NKH.1 (CD56), was elevated, but the killing of K562 tumor cells per CD56 cell was significantly diminished. Lymphoproliferative responses after stimulation with phytohemagglutinin and pokeweed mitogen were decreased in most patients when compared with those in normal controls, as was the production of gamma interferon following mitogen stimulation. Lymphocyte phenotypic marker analysis of peripheral blood lymphocytes showed that there were significant differences between patients with CFS and controls. There was an increase in the percentage of suppressor-cytotoxic T lymphocytes, CD8, and a proportionally larger increase in the number of CD8 cells expressing the class II activation marker. Most patients had an elevated number of CD2 cells which expressed the activation marker CDw26. The numbers of CD4 cells and the helper subset of CD4+ CD29+ cells in patients with CFS were not different from those in controls. There was, however, a significant decrease in the suppressor inducer subset of CD4+ CD45RA+ cells. The numbers of B cells, CD20 and CD21, were elevated, as were the numbers of a subset of B cells which coexpressed CD20 and CD5. The pattern of immune marker abnormalities observed was compatible with a chronic viral reactivation syndrome.",
author = "Klimas, {N. G.} and Salvato, {F. R.} and R. Morgan and Fletcher, {M. A.}",
year = "1990",
month = "6",
day = "18",
language = "English",
volume = "28",
pages = "1403--1410",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Immunologic abnormalities in chronic fatigue syndrome

AU - Klimas, N. G.

AU - Salvato, F. R.

AU - Morgan, R.

AU - Fletcher, M. A.

PY - 1990/6/18

Y1 - 1990/6/18

N2 - The chronic fatigue syndrome (CFS), formerly known as chronic Epstein-Barr virus syndrome, is a clinical state of some complexity and uncertain etiology. In order to characterize in a comprehensive manner the status of laboratory markers associated with cellular immune function in patients with this syndrome, 30 patients with clinically defined CFS were studied. All of the subjects were found to have multiple abnormalities in these markers. The most consistent immunological abnormality detected among these patients, when compared with normal controls, was low natural killer (NK) cell cytotoxicity. The number of NK cells, as defined by reactivity with monoclonal antibody NKH.1 (CD56), was elevated, but the killing of K562 tumor cells per CD56 cell was significantly diminished. Lymphoproliferative responses after stimulation with phytohemagglutinin and pokeweed mitogen were decreased in most patients when compared with those in normal controls, as was the production of gamma interferon following mitogen stimulation. Lymphocyte phenotypic marker analysis of peripheral blood lymphocytes showed that there were significant differences between patients with CFS and controls. There was an increase in the percentage of suppressor-cytotoxic T lymphocytes, CD8, and a proportionally larger increase in the number of CD8 cells expressing the class II activation marker. Most patients had an elevated number of CD2 cells which expressed the activation marker CDw26. The numbers of CD4 cells and the helper subset of CD4+ CD29+ cells in patients with CFS were not different from those in controls. There was, however, a significant decrease in the suppressor inducer subset of CD4+ CD45RA+ cells. The numbers of B cells, CD20 and CD21, were elevated, as were the numbers of a subset of B cells which coexpressed CD20 and CD5. The pattern of immune marker abnormalities observed was compatible with a chronic viral reactivation syndrome.

AB - The chronic fatigue syndrome (CFS), formerly known as chronic Epstein-Barr virus syndrome, is a clinical state of some complexity and uncertain etiology. In order to characterize in a comprehensive manner the status of laboratory markers associated with cellular immune function in patients with this syndrome, 30 patients with clinically defined CFS were studied. All of the subjects were found to have multiple abnormalities in these markers. The most consistent immunological abnormality detected among these patients, when compared with normal controls, was low natural killer (NK) cell cytotoxicity. The number of NK cells, as defined by reactivity with monoclonal antibody NKH.1 (CD56), was elevated, but the killing of K562 tumor cells per CD56 cell was significantly diminished. Lymphoproliferative responses after stimulation with phytohemagglutinin and pokeweed mitogen were decreased in most patients when compared with those in normal controls, as was the production of gamma interferon following mitogen stimulation. Lymphocyte phenotypic marker analysis of peripheral blood lymphocytes showed that there were significant differences between patients with CFS and controls. There was an increase in the percentage of suppressor-cytotoxic T lymphocytes, CD8, and a proportionally larger increase in the number of CD8 cells expressing the class II activation marker. Most patients had an elevated number of CD2 cells which expressed the activation marker CDw26. The numbers of CD4 cells and the helper subset of CD4+ CD29+ cells in patients with CFS were not different from those in controls. There was, however, a significant decrease in the suppressor inducer subset of CD4+ CD45RA+ cells. The numbers of B cells, CD20 and CD21, were elevated, as were the numbers of a subset of B cells which coexpressed CD20 and CD5. The pattern of immune marker abnormalities observed was compatible with a chronic viral reactivation syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0025322432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025322432&partnerID=8YFLogxK

M3 - Article

C2 - 2166084

AN - SCOPUS:0025322432

VL - 28

SP - 1403

EP - 1410

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 6

ER -